
(12) UK Patent Application (19) GB (11) 2 094 142 A

- (21) Application No 8107156
(22) Date of filing 6 Mar 1981
(43) Application published
15 Sep 1982
(51) INT CL³
A61K 31/52 31/195
C07C 101/24
C07D 473/08
(52) Domestic classification
A5B 170 180 20X 20Y 295
29Y 386 38Y J
C2C 1422 20Y 214 247 250
252 25Y 29X 29Y 321 32Y
351 352 386 387 386 628
630 635 761 764 AA LR TL
(56) Documents cited
GB 1272881
GB 1155940
GB 1101104
GB 1056116
GB 0624693
The Extra Pharmacopoeia
(Martindale), 27th Edition
p. 288 under
"Theophylline Sodium
Glycinate".
(58) Field of search
A5B
(71) Applicants
Laboratories for Applied
Biology Limited,
91 Amhurst Park,
London N16 5DR.
(72) Inventors
Abraham Freedman
(74) Agents
Boulton Wade and Tennant,
27 Fumival Street,
London EC4A 1PQ.

(54) Injectable solution containing
theophylline and a basic amino acid

(57) An injectable solution comprising
a basic amino acid and theophylline, for
use in the treatment of cardiac asthma
and allergic asthma. The basic amino
acid is especially lysine. Also disclosed
is a compound formed by reaction of
lysine and theophylline.

GB 2 094 142

SPECIFICATION

Injectable solution containing theophylline

5 The present invention relates to injectable solutions. It is well known that a mixture of theophylline and ethylenediamine (known as aminophylline) is used in the treatment of bronchial spasm and relaxes involuntary muscle. Aminophylline can be adminis-
 10 tered by intravenous injection in which case a sterile solution with a pH of from 9.2 to 9.6 is normally employed. Aminophylline can also have unpleasant side effects such as nausea, vomiting, hyperventilation and palpitations.

15 Theophylline has also been used for clinical purposes in combination with salts containing metal cations such as sodium. This can increase the solubility of theophylline in water but the presence of metal ions such as sodium is thought to be
 20 undesirable.

The present invention provides an injectable solution comprising a basic amino acid, for example lysine or arginine and theophylline.

A preferred amino acid is lysine although any
 25 naturally occurring basic amino acid, preferably one which occurs naturally in the human body and is thus readily metabolised may be suitable. The present invention will be illustrated in more detail with reference to the following Example.

30

Example

Our studies have indicated that when lysine and theophylline are combined in solution, a novel complex is formed, which will be referred to herein
 35 as Lysinium Theophyllinate. The presence of a complex of some kind has been indicated by ultra-violet spectroscopy, and it should be understood that the invention includes within its scope this novel compound *per se* as well as a solution thereof, for
 40 example an aqueous solution.

Our investigations indicate that such an aqueous solution containing theophylline in combination with lysine has significant advantages when used for
 45 injections in the treatment of complaints such as allergic asthma and cardiac asthma as compared with the conventional aminophylline.

These advantages include the absence of the toxic ethylenediamine molecule, and the fact that solu-
 50 tions having a pH which approaches more closely that of the blood can readily be prepared. It is also believed that the solution of the present invention is more readily utilised in the bloodstream.

The molar ratio of lysine to theophylline in the injectable solution is preferably approximately
 55 0.75:1.

The following is an Example of the preparation of an injectable solution according to the invention.

Example

be terminally sterilised by autoclaving. Ultraviolet spectroscopy indicated the presence in the solution of a complex, Lysinium Theophyllinate. The solution provided a readily assimilable injectable solution
 70 including theophylline and not having the toxic effects attributable to ethylenediamine.

It is envisaged that the novel complex may be utilised for topical application, for example as a nasal spray for the treatment of asthma and as a
 75 rectal suppository for the same treatment.

CLAIMS

1. An injectable solution comprising a basic
 80 amino acid and theophylline.
2. A solution as claimed in claim 1 wherein the amino acid is lysine.
3. A solution as claimed in claim 1 or claim 2 wherein the molar ratio of lysine to theophylline is
 85 approximately 0.75:1.
4. The use of a solution as claimed in any of the preceding claims in the treatment of cardiac asthma and allergic asthma.
5. A compound formed by the reaction of lysine
 90 and theophylline.
6. A process for preparing a compound as claimed in claim 5 which comprises reacting lysine with theophylline.
7. A solution as claimed in claim 1 substantially
 95 as hereinbefore described in the Example.

Printed for Her Majesty's Stationery Office, by Croydon Printing Company Limited, Croydon, Surrey, 1982.
 Published by The Patent Office, 25 Southampton Buildings, London, WC2A 1AY, from which copies may be obtained.